HARESH S. JHANGIANI, M.D., F.A.C.P., M.B.A.
CAREER MISSION STATEMENT
To tender compassionate and exceptional quality healthcare to all my patients and provide the necessary leadership, knowledge, and skills to develop and maintain a comprehensive research program for the benefit of all cancer patients.
PROFESSIONAL EXPERIENCE
2002 – Present COMPASSIONATE CANCER CARE MEDICAL GROUP, INC.
Corona, Fountain Valley, and Riverside, California
Private practice with multiple sites in Orange and Riverside Counties.
Serves as a consultant to area’s primary care physicians and surgeons.
Participate in clinical research and regional cancer center programs.
Director-American Home Health Hospice, Santa Ana, CA
2002 – Present CORONA REGIONAL CANCER CENTER - Medical Director
Corona, California
Oversee the cancer program, coordinate community lecture, establish a research program, enhance the visibility of the cancer center and minimize out migration of patients from the local community
1988 – 2002 PACIFIC COAST HEMATOLOGY/ONCOLOGY MEDICAL GROUP
Fountain Valley, California
Private practice with multiple sites in Orange and Riverside Counties.
Serves as a consultant to area’s primary care physicians and surgeons.
Participate in clinical research and regional cancer center programs.
Director-American Home Health Hospice, Santa Ana, CA
1995 - 1999 FOUNTAIN VALLEY REGIONAL HOSPITAL AND MEDICAL CENTER
Fountain Valley, California
Director, Peripheral Stem Cell Transplant Program
Oversee the medical center’s peripheral stem cell transplant program. Provide clinical supervision of induction, chemotherapy, pheresis, high dose chemotherapy, re-infusion of stem cells and recovery. Responsibilities include oversight of clinical staff and research protocols, education and training of physician and nursing staff, as well as total quality management of patients. Accomplishments to date include development of clinical program policy/procedure manual, establishment of research protocols and space/equipment planning for the outpatient center.
MEDICAL LEADERSHIP POSITIONS
Chairman, Working Tumor Board 2000-2003
Orange Coast Memorial Hospital
Chairman, Working Tumor Board 1998-2003, 2006-present
Fountain Valley Regional Hospital and Medical Center
Chairman, Cancer Committee 2005-present
Riverside Community Hospital
Chairman, Cancer Committee 2006-present
Fountain Valley Regional Hospital and Medical Center
Member, Tissue Transfusion Committee 1996-2000
Fountain Valley Regional Hospital and Medical Center
Member, Quality of Patient Care Committee 1996-2000
Fountain Valley Regional Hospital and Medical Center
Medical Director 2002-present
Corona Regional Medical Center
Chairman, Cancer Committee 2002-present
Corona Regional Medical Center
Chairman, Working Tumor Board 2006-present
Corona Regional Medical Center
Member, Clinical Research Committee 1998-2002
Orange County Regional Cancer Center
HOSPITAL AFFILATION APPOINTMENTS
Fountain Valley Regional Hospital and Medical Center
Fountain Valley, California
Hoag Memorial Hospital
Newport Beach, California
Irvine Medical Center
Irvine, California
Corona Regional Medical Center
Corona, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Los Angeles County/USC Medical Center
Los Angeles, California
Orange Coast Memorial Hospital
Fountain Valley, California
Huntington Beach Hospital
Huntington Beach, California
UCI Medical Center
Irvine, California
Parkview Hospital
Riverside, California
Riverside Community Hospital
Riverside, California
Chapman Medical Center
Orange, California
CLINICAL RESEARCH ACTIVITY
BLADDER CANCER
A Randomized Phase III Study of Gemcitabine plus Cisplatin versus MVAC Chemotherapy in Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium.
Sub-Investigator: Haresh Jhangiani, M.D.
Interleukin 2 in an Alternative Dose: Treatment of Patients with Metastatic Renal Cell Cancer with Low Dose Proleukin.
Sub-Investigator: Haresh Jhangiani, M.D.
BREAST CANCER
Phase III trial of novel XXXXX plus capecitabine vs. capecitabine alone in patients with advanced breast cancer in previously treated with anthracycline and a taxine
Principal Investigator: Haresh Jhangiani, MD
A Randomized, open-label phase III, study of RPR109881-IV vs. XXXXX in patients with metastatic breast cancer progressive after taxanes and anthracycline therapy
Principal Investigator: Haresh Jhangiani, MD
A randomized, double-blind, parallel group, multicenter, phase III study comparing efficacy and tolerability of XXXXX 500 mg w/ XXXXX 250 mg in postmenopausal women with ER+ positive advanced breast cancer progressing or relapsing after previous therapy
Principal Investigator: Haresh Jhangiani, MD
Randomized Trial of Gemcitabine Plus Docetaxel vs. Docetaxel Plus Capecitabine in Metastatic Breast Cancer in 1st and 2nd Line Patients
Sub-Investigator: Haresh Jhangiani, MD
An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women with ER+ and/or PR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy
Principal Investigator: Haresh Jhangiani, MD
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegfilgrastim on the Incidence of Febrile Neutropenia in Subjects with Advanced Breast Cancer Treated with Single Agent Docetaxel
Principal Investigator: Glen Justice, MD
Sub-Investigator: Haresh Jhangiani, MD
A Multicenter Phase III Randomized Trial Comparing Docetaxel In Combination With Doxorubicin And Cyclophosphamide (TAC) Versus Doxorubicin And Cyclophosphamide Followed By Docetaxel (ACT) As Adjuvant Treatment Of Operable Breast Cancer HER2NEU Negative Patients With Positive Auxiliary Lymph Nodes
Principal Investigator: Haresh Jhangiani, M.D.
A Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (ACT) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (ACTH) and with Docetaxel, Platinum Salt and Trastuzumab (TCH) in the Adjuvant Treatment of Node Positive and High Risk Node Negative Patients with Operable Breast Cancer Containing the HER2NEU Alteration
Principal Investigator: Haresh Jhangiani, M.D.
A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere®) and Trastuzumab (Herceptin®) with Docetaxel (Taxotere®), Carboplatin, and Trastuzumab (Herceptin®) as First line Chemotherapy for Patients with Advanced Breast Cancer Containing the HER2Gene Amplification
Principal Investigator: Haresh Jhangiani, M.D.
Phase III Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Versus Epirubicin/Taxane (Concurrent Chemotherapy) Adjuvant Treatment Operable, Node-Positive Breast Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Clinical Outcomes in Patients with HER2 Gene-Amplified Metastatic Breast Cancer Treated with First-Line Herceptin® in Combination with a Taxane: A Phase IV, Prospective, Community-Based Study
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
The Traviota Study: Trastuzumab (Herceptin®) and Either Vinorelbine (Navelbine®) or Taxane-Based Chemotherapy in Patients with HER2 Overexpressing Metastatic Breast Cancer: A Randomized Phase III Study
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed By Paclitaxel or Docetaxel Given Weekly Or Every 3 Weeks In Patients With Auxiliary Node-Positive Breast Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Randomized Comparison of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Multicenter, Open-Label, Randomized Study Of Three Schedules Of Weekly Taxol Induction Therapy Followed By Weekly Taxol Maintenance Therapy In Metastatic Breast Cancer Patients
Principal Investigator: Haresh Jhangiani, M.D.
An Epidemiologic Study Of Breast Cancer Risk Assessment Along With Breast Cancer Prevention And The Use Of Tamoxifen At The Center For Breast Care Of Orange County Regional Cancer At Fountain Valley Medical Center Beta Site For Tenet Health Care
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Comparison of CGS-16949A vs. Megestrol Acetate in Post-Menopausal Women With Breast Carcinoma.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Daunoxome For The Treatment of Metastatic Breast Cancer (Phase II).
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Comparative Trial of Droloxifene and Tamoxifen as First-line Hormonal Therapy in Women With Advanced Breast Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Comparison of Two Doses (0.5mg. And 2.5mg) of Letrozole (CGS 20267) Versus Megestrol Acetate in Postmenopausal Women With Advanced Breast Cancer.
Principal Investigator: Haresh Jhangiani, M.D.
Aredia (Pamidronate Disodium) Comparative Trial of Aredia Versus Placebo for Prevention of Skeletal-Related Complications in Patients With Breast Cancer and Lytic Bone Lesions Treated With Chemotherapy.
Investigator: Haresh Jhangiani, M.D.
Phase II Open-Label, Multicenter Study of Single Agent Doxil in the Treatment of Patients With Anthracycline Resistant Locally Advanced or Metastatic Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Assessment of the Predictive Value of the Extreme Drug Resistance (EDR) Assay in Patients Receiving Paclitaxel for Metastatic Breast Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Randomized, Double-Blind Trial Comparing Arimidex Alone With Nolvadex Alone With Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Comparison of the Effect of SCH 57050 and Anastrazole in Subjects With Breast Cancer Relapsing After an Initial Response to Tamoxifen or Showing Progression After Tamoxifen Given as Adjuvant to Surgery: A Prospective Double-Blind Phase III Trial.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Daunoxome as First Line Therapy for the Treatment of Metastatic Breast Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Phase I/II Antibody MDX-H210 Combined With G-CSF in Patients With Metastatic Cancer That Over expresses HER2/neu.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Adriamycin and Cytoxan Followed by Taxol or Taxotere either Weekly or Every Three Weeks for Women with Stage IIA, IIB or IIIA Breast Cancer with Six Lymph Nodes Removed.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Medroxyprogesterone Acetate + Tamoxifen vs Observation + Tamoxifen in Post-Menopausal Women with Breast Cancer T1-3 N0-1 M0
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Study of Tamoxifen and Raloxifene (STAR) for Prevention of Breast Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Open-Label Study of Femara (2.5 mg) Daily for Patients with ER Receptor Positive Advanced Breast Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
COLORECTAL CANCER
A Phase 2, Open-label., Randomized Clinical Trial of Skin Toxicity Treatment of Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly with Panitumumab.
Principal Investigator: Haresh Jhangiani, M.D.
A multicenter, randomized double-blind placebo controlled phase III study of the efficacy of Xaliproden in preventing
the neurotoxicity of oxaliplatin in first-line treatment of patients with metastatic colorectal cancer treated with
oxaliplatin/5-FU/LV
Randomized, open-label phase IIIB trial comparing two methods of Avastin-based induction/maintenance therapy for the first line treatment of MCRC
Principal Investigator: Haresh Jhangiani, MD
A randomized, open-label, controlled, clinical trial of chemotherapy and Bevacizumab with/without XXXXX in the first line treatment of patients with mCRC
Principal Investigator: Haresh Jhangiani, MD
A randomized, double-blind, placebo-controlled, phase III study in patients with mCRC or rectum who are receiving first-line chemotherapy with oxaliplatin/5-FU/leukovorine and PTK787/zk xxxxx or placebo
Principal Investigator: Haresh Jhangiani, MD
An Open Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (“XELOX”) versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leukovorin with Intravenous Oxaliplatin (Q2W) (“FOLFOX4”) as First Line Treatment for Patients with Locally Advanced or Metastatic Colorectal Cancer.
Principal Investigator: Haresh S. Jhangiani, M.D.
A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as a Second Line Treatment in Patients with Metastatic EGFR-Positive Colorectal Cancer.
Principal Investigator: Haresh S. Jhangiani, M.D.
Phase III Intergroup Study, Postoperative Evaluation of 5-FU By Prolonged Venous Infusion Prior To And Following Combined Prolonged Venous Infusion Plus Pelvic XTR Versus Bolus 5-FU Plus Leucovorin Plus Levamisole Prior To And Following Combined Pelvic XRT In Patients With Rectal Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination with Standard Chemotherapy in Subjects with mCRC; Second-line Treatment of rhuMAb VEGF with or without Chemotherapy for Subjects whose Cancer Progressed on the Protocol
Principal Investigator: Haresh Jhangiani, M.D.
An Open-Label, Single-Arm Trial of Patients with Metastatic Colorectal Cancer Receiving Irinotecan, 5-Fluorouracil, and Leucovorin Followed by Leukine® (Sargramostim), a Recombinant Human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Hoffmann-La Roche MO16461: An Open-Label Phase II Study of Intermittent Oral Capecitabine in Combination with Intravenous Irinotecan (Q3W) in Patients with Advanced and/or Metastatic Colorectal Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Phase II Trial of Trimetrexate, 5-Flurouracil and Leucovorin in Previously Treated Patients With Unresectable or Metastatic Colorectal Cancer.
Principal Investigator: Haresh Jhangiani, M.D.
A Multicenter, Randomized Phase II Trial of Gemcitabine Plus 5FU/Leucovorin (FFG) vs. Oxaliplatin Plus 5FU/Leucovorin (FOLFOX4) as therapy for Patients with Metastatic Colorectal Cancer
Principal Investigator: Haresh Jhangiani, M.D.
Therapeutic and Biological Effects of the Bispecific Antibody MDX-H210 Combined With GM-CSF in Patients With HER2/neu Positive Advanced Colorectal Carcinoma.
Principal Investigator: Haresh Jhangiani, M.D.
A Randomized Multicenter Phase III Trial of Irinotecan in Combination with Three Different Methods in Administration of Fluoropyrimidine: Infusional 5-FU (FOLFIRI), Bolus 5-FU (Day 1 & 8), and Oral Capecitabine (Day 1-14); with Celecoxib versus Placebo as First Line Treatment for Patients with Metastatic Colorectal Cancer
Principal Investigator: Haresh Jhangiani, M.D.
A Prospective, Randomized, Multi center Phase III Clinical Trial Comparing the Effects of PANOREX (17-1A Monoclonal Antibody) Injection Plus 5-Fluorouracil-Based-Chemotherapy Versus 5-Fluorouracil-Based-Chemtherapy Alone in Patients With Surgically Resected Stage III Carcinoma of the Colon.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Double Blind, Placebo Controlled, Randomized Phase III Trial of 5-FU and Leucovorin + Neutrexin in Previously Untreated Patients With Advanced Colorectal Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Compassionate Use Study of Oxaliplatin in the Treatment of Metastatic Colorectal Carcinoma
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Phase II, Randomized, Multicenter Comparison of the Efficacy of Oxaliplatin in Four Schedules of 5-FU with and without Leucovorin in Previously Untreated Advanced Colorectal Cancer
Principal Investigator: Haresh Jhangiani, M.D.
A Phase II Study of Orzel Given as a Twice Daily Regimen in the Treatment of Patients with Metastatic Colorectal Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
An Open-Label, Single-Arm Trial of Patients with Metastatic Colorectal Cancer Receiving Irinotecan, 5-Fluorouracil, and Leucovorin Followed by Leukine, a Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Treatment Access Program with Oxaliplatin for Previously Treated Colorectal Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
An Open-Label Randomized Phase III Study Comparing Xeloda with IV Bolus 5-FU Combination with Low Dose Leucovorin as Adjuvant Chemotherapy Patients who Underwent Surgery for Dukes C Colon Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
CERVICAL CANCER
Radiation plus Cisplatin versus Radiation plus 5-FU Infusion Protracted in the Treatment of Stage IIB, IIIB, and IVA Cervical Cancer.
Principal Investigator: Haresh Jhangiani, M.D.
ENDOMETRIAL CANCER
Cisplatin plus Doxorubicin or Cisplatin plus Doxorubicin plus Taxol with GCSF Support in the Treatment of Stage III-IV Primary or Recurrent Endometrial Cancer.
Principal Investigator: Haresh Jhangiani, M.D.
Estrogen Replacement Therapy versus Placebo in the Treatment of Stage I-II Endometrial Adenocarcinoma.
Principal Investigator: Haresh Jhangiani, M.D.
HEAD AND NECK CANCER
Phase III of Radiation Therapy + or - Amifostine in Patients With Head and Neck Cancer.
Principal Investigator: Donald Karon, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
GASTRIC CANCER
Open Label, Randomized Multicenter Phase II/III Study of Docetaxel in Combination with Cisplatin (CDDP) or Docetaxel in Combination with 5-FU and CDDP Compared to the Combination of CDDP and 5-FU in Patients with Metastatic or Locally Recurrent Gastric Cancer Previously Untreated with Chemotherapy for Advanced Disease.
Principal Investigator: Lalita Pandit, M.D./ Glen R. Justice, MD
Sub-Investigator: Haresh Jhangiani, M.D.
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients with Gastric or Rectal Cancers Undergoing Preoperative Chemo radiation Followed by Surgery
Principal Investigator: Haresh Jhangiani, MD
HEMATOLOGIC MALIGNANCIES
CBRG # NIP 02-01 Pentostain, Cyclophosphamide and Rituximab (PCR) for B-Cell Chronic lymphocytic Leukemia (CLL) and Small B-Cell Lymphocytic (SLL): Four Phase II Trials with patient stratification based on prior therapy
Principal Investigator: Haresh S. Jhangiani, M.D
A Prospectively Randomized, Phase III, Multicenter, Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin Therapeutic Regimen Plus Rituxan Compared with Rituxan Alone in Patients with Relapsed or Refractory Follicular Non-Hodgkin’s Lymphoma
Principal Investigator: Haresh Jhangiani, MD
Treatment of Intermediate / High Grade NHL with Rituxan Combined With ESHAP Chemotherapy
Principal Investigator: Glen R. Justice, MD
Sub-Investigator: Haresh Jhangiani, M.D.
Daunoxome and Dexamethasone Therapy With GM-CSF Support for Patients With Multiple Myeloma: A Phase II International Oncology Study Group (ISOG) Protocol.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Multi center, Open-Label Study Evaluating the Efficacy and Safety of Rituxan (Rituximab) in Combination with Six Cycles of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) Followed by Rituxan Maintenance as Initial Therapy for Patients with Advanced Stage Indolent Non-Hodgkin’s Lymphoma
Principal Investigator: Haresh Jhangiani, M.D.
A Multi Center Open Label Study Evaluating the Efficacy and Safety of Rituxan (Rituximab) in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Chemotherapy followed by Rituxan Maintenance as Initial Therapy for Patients with Aggressive Non-Hodgkin’s Lymphoma
Principal Investigator: Haresh Jhangiani, M.D.
A Randomized Phase III Trial of ABVD versus Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin’s Disease with 0-2 Risks Factors
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
HIGH DOSE THERAPY
Autologous Stem Cell Transplantation for Patients With Acute Myeloid Leukemia Beyond First Remission: A Randomized Trial of Post-Transplant Therapy With Interleukin-2 Versus Observation, Phase III.
Principal Investigator: Haresh Jhangiani, M.D.
Phase II Study of High Dose Melphalan With Hematopoietic Stem Cell Support and GM-CSF in Refractory Multiple Myeloma.
Principal Investigator: Haresh Jhangiani, M.D.
Sequential High-Dose Cyclophosphamide and High Dose BCNU/Etoposide/Melphalan Followed by Hematopoietic Rescue in Patients With Multiple Myeloma.
Principal Investigator: Haresh Jhangiani, M.D.
High Dose Chemotherapy and Hematopoietic Stem Cell Rescue as Consolidation Therapy During First Complete or Partial Remission in Patients With Poor Risk Aggressive Lymphoma.
Principal Investigator: Haresh Jhangiani, M.D.
High Dose Etoposide, Cyclophosphamide and Either Fractionated Total Body Irradiation or Carmustine With Autologous Bone Marrow Rescue for Refractory or Relapsed Hodgkin’s Disease.
Principal Investigator: Haresh Jhangiani, M.D.
Sequential High Dose Cyclophosphamide and High Dose BCNU/Etoposide/Melphalan Followed by Hematopoietic Rescue in Patients With Lymphoma in “Sensitive” Relapse.
Principal Investigator: Haresh Jhangiani, M.D.
LUNG CANCER
A RANDOMIZED PHASE 2 TRIAL OF PACLITAXEL, CARBOPLATIN AND BEVACIZUMAB WITH OR WITHOUT PF-3512676 AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
A Randomized Controlled Trial Comparing Safety and Efficacy of XXXXX and XXXXX plus or minus XXXXX (BAY 43-9006) in chemonäive patients with Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Haresh Jhangiani, MD
“DARTMOUTH STUDY” A Multicenter, Randomized Phase III Study of Taxotere and Carboplatin VERSUS Taxotere and Gemcitabine in Patients with Advanced Non Small Lung Cancer.
Principal Investigator: Haresh Jhangiani, M.D.
Randomized phase III trial comparing Targretin capsules/Carboplatin/Paclitaxel vs. Carboplatin/Paclitaxel in chemotherapy-naïve patients with Advanced (IIIB with Pleural Effusion) or Metastatic Non Small Cell Lung Cancer
Principal Investigator: Haresh Jhangiani, M.D.
104864/535 A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer with Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
Principal Investigator: Haresh Jhangiani, M.D.
Phase 3 Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Principal Investigator: Haresh Jhangiani, M.D.
A Randomized Phase III Trial Surgery Alone or Surgery Plus Preoperative Paclitaxel / Carboplatin in Clinical Stage IB (T2N0), II (T1-2N1, T3N0) and Selected IIIA (t3N1) Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
An Open-Label, Multicenter, Non-Comparative Study of Topotecan as Single Agent. Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) in Patients With Small Cell Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M. D.
Evaluation of Docetaxel and Cisplatin With Filgrastim Support for the Treatment of Patients With Stage III or IV Non-small Cell Lung Cancer.
Principal Investigator: Haresh Jhangiani, M.D.
A Multi-Center Randomized Phase II Trial of Weekly Docetaxel plus Gemcitabine versus Weekly Paclitaxel plus Gemcitabine in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Phase IV, Open-Label, Prospective, Randomized, Multicenter Trial Comparing Quality of Life in Elderly Subjects receiving either Navelbine Injection, as a Single Agent or Best Supportive Care for the Treatment of Previously Untreated, Stage IV Non-Small Cell Lung Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
H3E-MC-JMEI: A Phase III Trial of Alimta versus Docetaxel in Patients Previously Treated with One Chemotherapy Regimen for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Phase III, Randomized, Double-Blind, Multi-Center Study of the Efficacy of Taxotere in Combination with Aptosyn versus Taxotere and Placebo in NSCLC Patients after Failure of Prior Platinum-Based Chemotherapy
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
An Open-Label, Multicenter, Randomized Phase III Study of Hycamtin (Topotecan) as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) Versus Second CAV In Patients With SCLC Who Have Relapsed at Least Three Months After Completion Of First-Line Therapy.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Randomized, Phase III Trial Comparing CPT-11 (Irinotecan HCL; Camptosar Injection)/ Cisplatin with Etoposide / Cisplatin in Patients with Previously Untreated, Extensive, Small-Cell Lung Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
An Expanded Access Clinical Program with ZD1839 (Iressa™) for Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Principal Investigator: Haresh Jhangiani, M.D.
The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study with Adjuvant BEC2 AND BCG.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Cell Pathways 028: A Phase III, Randomized, Double-Blind, Multi-Center Study of the Efficacy of Taxotere (Docetaxel) in Combination with Aptosyn (Exisulind) versus Taxotere (Docetaxel) and Placebo in Non-Small Cell Lung Cancer (NSCLC) Patients After Failure of Prior Platinum-Based Chemotherapy
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
SWOG9909: Positron Emission Tomography (PET) Imaging of Lung Cancer Response to Therapy in Patients Registered to 9900
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D
OVARIAN CANCER
Open-Label Multicenter, Randomized Phase III Study of Topotecan as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) Versus Taxol (Administered as a Three-Hour Infusion Every 21 Days) in Women With Advanced Epithelial Ovarian Carcinoma.
Principal Investigator: Glen Justice
Sub-Investigator: Haresh Jhangiani, M.D.
Topotecan plus Cisplatin Induction Therapy Followed by Taxol
Consolidation Therapy for the Treatment of Stage III & IV Epithelial Ovarian Cancer and Primary Peritoneal Cancer with In-Vitro Correlates of Response
Principal Investigator: Haresh Jhangiani, M.D.
PANCREATIC CANCER
Modulation of 5-Fluorouracil With Trimetrexate and Leucovorin in Advanced Pancreatic Cancer.
Principal Investigator: Lalita Pandit, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Phase III Randomized Study of RFS 2000 Versus Gemcitabine HCI in Chemonaive Pancreatic Cancer Patients
Principal Investigator: Haresh Jhangiani, M.D.
Phase III Randomized Study of RFS 2000 Versus 5-FU in Pancreatic Cancer Patients that have Progressive Disease Following Gemcitabine HCI Treatment
Principal Investigator: Haresh Jhangiani, M.D.
Janssen R115777-INT-16: A Randomized Phase II Trial to Evaluate the Efficacy of Gemcitabine plus R1157777 versus Gemcitabine plus Placebo on Time to Deterioration in Patients with Advanced Pancreatic Cancer.
Principal Investigator: Haresh Jhangiani, M.D.
A Phase III Trial of Alimta Plus Gemzar versus Gemzar in Patients with Unresectable or Metastic Cancer of the Pancreas
Principal Investigator: Glen Justice
Sub-Investigator: Haresh Jhangiani, M.D.
PROSTATE CANCER
"A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy Naïve
Principal Investigator: Haresh S. Jhangiani, M.D.
Phase III randomized, open-label study of CG1940 and CG8711 vs. docetaxel & estrumustine in patients with metastatic hormone-refractory prostate cancer who are chemotherapy naïve
Principal Investigator: Haresh Jhangiani, MD
A multicenter evaluation of combination chemotherapy and hormonal therapy using Taxol, Carboplatin, Estramustine and Lupron followed by definitive therapy for high-risk, locally advanced Prostate Cancer
Principal Investigator: Haresh S. Jhangiani, M.D.
A Phase II Study to Determine the Biological Effects of Biospecific Antibody MDX-H210 (520C9XH22) Combined With GM-CSF in Patients With Advanced Prostate Cancer or Renal Cell Carcinomas That Express HER2/neu.
Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Phase II Trial of Epirubicin and Docetaxel in Patients with Hormone Refractory Prostate Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
SWOG9346: A Phase III Trial of Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
SWOG9246: A Phase II Trial of Flutamide Withdrawal After Patients with Metastatic Prostate Cancer Have Had Disease Progression
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
SUPPORTIVE THERAPY
An Open Label Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Severe Thrombocytopenia Due to Multi Cycle Chemotherapy in Adult Subjects with Lymphoma.
Principal Investigator: Haresh S. Jhangiani, M.D
Double-Blind, Placebo-Controlled, Dose-Finding Study of the Effect of GTx-024 on Muscle Wasting (cachexia) in Patients with Cancer.
A Pivotal Phase III, Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi™ for the Prevention of Acute-onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following the Administration of Either Moderately or Highly Emetogenic Chemotherapy Regimens.
Surpass Study An Open Label Study to Assess Symptom Burden in Subjects with nonmyeloid Malignancies Receiving Chemotherapy and AranespTM
Principal Investigator: Haresh S. Jhangiani, M.D
PR00-03-006 A Double Blind, Randomized, Placebo-Controlled Study of The Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients with Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery.
Principal Investigator: Haresh S. Jhangiani, M.D
PR02-27-015 An Open-Labeled Pilot Study To Evaluate The Effects of High Dose PROCRIT® (Epoetin alfa) In Maintaining Hemoglobin Levels in Anemix Cancer Patients Receiving Chemotherapy On a Weekly or Every 4 Week Regimen.
Principal Investigator: Haresh S. Jhangiani, M.D
PR0-02-016 An Open Labeled Pilot Study To Evaluate The Effects Of High Dose PROCRIT® (Epoetin alfa) In Maintaining Hemoglobin Levels inAnemic Cancer Patients Receiving Chemotherapy on a Every 3 Week Regimen.
Principal Investigator: Haresh S. Jhangiani, M.D
PR00-27-012/225-05-00 Phase II: An Open Label Study of PROCRIT® (Epoetin Alfa) in Women Undergoing Adjuvant Chemotherapy for Stage I,II or III Breast Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Double Blind, Multicenter, Crossover Study Comparing the Efficacy and Safety of Intravenous (IV) Granisetron Hydrochloride 10ug/kg With IV Ondansetron Hydrochloride 32 mg in the Prevention of Nausea and Vomiting Induced by IV Cyclophosphamide and Doxorubicin Chemotherapy in Patients With Breast Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
PALO-99-04: A Randomized, Double-Blind Comparison of Single-Dose Ondansetron Intravenous Versus Single-Dose Intravenous Granisetron on the Prevention of Nausea And Vomiting With High-Dose Cisplatin Chemotherapy.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Randomized, Double-Blind Comparison of Oral Ondansetron and Compazine for the Prevention of Nausea and Vomiting Associated With Moderately-Emetogenic Chemotherapy.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Pilot Study to Evaluate the Response Rate of Procrit at 40,000 Units Once Weekly in Anemic Cancer Patients Not Receiving Chemotherapy
Principal Investigator: Haresh Jhangiani, MD
A Randomized, Double-Blind, Placebo-Controlled Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of MK-0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy
Principal Investigator: Haresh Jhangiani, MD
An Open-Label, Uncontrolled, Multicenter Study to Evaluate the Efficacy and Safety of Two 1mg Tablets of Kytril (Granisetron Hydrochloride) Given Once Prior to Chemotherapy in the Prevention of Nausea and Vomiting Induced by Cisplatin-Based Chemotherapy.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Double Blind, Parallel, Multicenter Study Comparing the Efficacy And Safety of Intravenous Granisetron and Ondansetron in the Prophylaxis of Nausea and Emesis Induced by Cisplatin-Based Chemotherapy.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Phase III Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin in Preventing CRCs when Given Daily to Cancer Patients with Central Venous Catheters
Principal Investigator: Haresh Jhangiani, M.D.
A Double-Blind, Multicenter, Parallel Study, Comparing the Efficacy and Safety of Oral Granisetron Hydrochloride 2 mg With IV Ondansetron Hydrochloride 32mg, Given Once, in the Prevention of Nausea and Vomiting Induced by IV Cyclophosphamide-Based or Carboplatin-Based Chemotherapy In Patients With Malignant Disease.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D
A Double-Blind, Multicenter, Parallel Study, Comparing the Efficacy and Safety of Oral Granisetron Hydrochloride 2 mg With Intravenous Ondansetron Hydrochloride 32mg, Given Once, Prior to Chemotherapy in the Prevention of Nausea and Vomiting Induced by Cisplatin-Based Chemotherapy.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Randomized, Double-Blind, Placebo-Controlled Comparison of the Analgesic Activity of Valdecoxib 40 mg BID as Add On Therapy to Opioid Medication in Patients with Chronic Cancer Pain.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Randomized Dose-Finding Study of NESP Administered by SQ Injection for the Treatment of Anemia in Subjects with Solid Tumors Receiving Multicycle Chemotherapy
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Phase IV Open Label Study of Procrit in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Double Blind, Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor, H376/95 versus Standard Therapy in Patients with Active, Symptomatic DVT with or without PE.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Dose-Finding Study of NESP Administered by SQ Injection for the Treatment of Anemia of Subjects with Chronic Anemia of Cancer.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Randomized, Open-Label, Multicenter Study of Subcutaneous and Intravenous Administration of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) for the Treatment of Anemia in Subjects with Non-Myeloid Malignancies Receiving Multicycle Chemotherapy
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Randomized Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) and rHuEPO for the Treatment of Anemia in Subjects with Non-Myeloid Malignancies Receiving Multi-Cycle Chemotherapy
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
A Phase III, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Innopep (Tinzaparin Sodium) for Primary Prevention of Venous Thromboembolism and Reduction of Mortality in Subjects with Advanced Cancer
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
MISCELLANEOUS
A Phase I Study to Determine the Maximum Tolerated Dose. Pharmacokinetics and Biologic Effects of Bispecific Antibody MDX-H210 Combined With GCSF in Patients With Metastatic Cancer That Over expresses HER2/neu.
Principal Investigator: Glen Justice, M.D.
Sub-Investigator: Haresh Jhangiani, M.D.
Interleukin Eleven (Neumega rhIL-11 Growth Factor at a Dose of 50ug/kg
Subcutaneous) Once Daily for 14 Days vs. Placebo in Adult Cancer Patients Phase 3 Double-Masked, Randomized Study of Recombinant Human With Severe Thrombocytopenia Due to Chemotherapy
Investigator: Haresh Jhangiani, M.D.
Randomized, Double-Blind, Acyclovir-Controlled, Multicenter Study to Assess the Safety, Efficacy and Pharmacokinetics of Intravenous Penciclovir for the Treatment of Mucocutaneous Herpes Simplex Infection in Immuno-compromised Patients.
Principal Investigator: Glenn Justice, M.D
Sub-Investigator: Haresh Jhangiani, M.D.
EDUCATION
6/73 - 6/78 University of Bombay, India
M.B.B.S., Ranked second in class of 125 graduating medical students.
6/70 - 10/72 University of Bombay, India
Inter-Science, Major in Biology (Pre-Med)
9/03 – 8/05 University of California, Irvine – Paul Merage School of Business
Master of Business Administration
RESIDENCY
7/83 - 6/84 Kaiser Permanente, West Los Angeles, California
Internal Medicine
7/82 - 6/83 Martin Luther King, Jr./Drew Medical Center, Los Angeles, California
Pediatric
7/81 - 6/82 St. Joseph Mercy Hospital, Michigan
Internal Medicine
8/80 - 6/81 St. Joseph Mercy Hospital, Michigan
Pediatric
8/79 - 5/80 Nair Hospital, India
General Surgery
7/78 - 7/79 Nair Hospital, India
Rotating Internship
FELLOWSHIPS
7/87 - 6/88 University of Southern California, West Los Angeles, California
One-year Oncology
Duties include managing patients, supervising medical students and residents, seeing inpatients and outpatient consultations, and presenting cases.
7/85 - 6/87 Kaiser Permanente, (Sunset) Los Angeles, California
One-year Oncology - includes one month radiation oncology elective and three month elective at City of Hope
Duties include managing patients, supervising medical students and residents, seeing inpatient and outpatient consultations, arranging Lymphoma Board Conference and presenting cases.
Kaiser Permanente, (Sunset) Los Angeles, California
One-year Hematology - includes a rotation in bone marrow transplant unit.
7/84 – 6/85 Kaiser Permanente, West Los Angeles, California
Attending Staff – Emergency Room
PUBLICATIONS
· Evaluation of Docetaxel and Cisplatin With Filgrastim Support for the treatment of Patients With Stage III or IV Non-small Cell Lung Cancer H.Jhangiani, G.R.Justice, et al - American Society of Clinical Oncology, San Francisco, California, May 2001
Ring-Shaped Particle (RSP): A Tumor Marker for Lung and Ovarian Cancer Correlates Well as a Parameter of Tumor Response to Therapy: R. Guerrero, G. Justice, D. Rounds, K. Shah, H. Jhangiani, N. Tchekmedyan, P. Coluzzi, F. Dexeus, T. White, E. Bald-American Society of Clinical Oncology, Orlando, Florida, April 1993
Ring-Shaped Particle (RSP): An Accurate Tumor marker for Breast, Lung and Ovarian Carcinoma: R. Guerrero, G. Justice, D. Rounds, K. Shah, H. Jhangiani, N. Tchekmedyian, P. Coluzzi, F. Dexeus, T. White, E. Bald-European Association of Cancer Research - 12th Annual Meeting, Brussels, Belgium, April 1993
Ring-Shaped Particle (RSP): A New Tumor Marker Published, USA for Breast, Lung Cancer That Accurately Discriminated between Primary Lung Cancer and Normal s, Including Chronic Obstructive Pulmonary Disease (COPD) and Smokers: Presented to American Society of Clinical Oncology, San Diego, CA May 1992.
Finding an effective dose of fentanyl effervescent buccal tablets: Combined results of open-label titration: M.S. Wertheim, H. Jhangiani, G. Niebler, V. Charu – Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June Supplement), 2006.
BOARD CERTIFICATION
Medical Oncology, November 1989
Internal Medicine, September 1988
LICENSURE
California License # A38872; DEA# AJ1756937 / DEA# BJ 7758658
Michigan License # 4301044717
RESEARCH AFFILIATIONS
Member of Southwest Oncology Group (SWOG)
Member of National Surgical Adjuvant Board and Bowel Project (NSABP)
Several Phase II-III trials for various pharmaceutical committees
Member of the City of Hope Sub-Investigators Panel
Chairman and Scientific Advisor to the Board for ClinicAid Research Management, Inc.
REGIONAL AFFILIATION
Regional Medicare Representative for the State of California for Medical Oncology Association of Southern California – California Oncology Consortium
SPEAKING AFFILIATIONS
Amgen Speakers Bureau - Aranesp
AstraZeneca Speakers Bureau – Iressa
Bristol Myers Squibb Oncology Speakers Bureau – Carboplatin
Roche Speakers Bureau – Xeloda
Eli-Lilly & Co. Speakers Bureau – Gemzar
OrthoBiotech Speakers Bureau – Procrit
ONS, Orange County Chapter, Speakers Bureau
Cephalon, Inc. – Speakers Bureau
Celgene Corp. – Speakers Bureau
Novartis Pharmaceuticals Corporation – Speakers Bureau
PRECEPTOR
USC/Norris Cancer Center - USC/LA County Medical Center
Leukemia Lymphoma Clinic
LIAISON POSITIONS
Assistant Clinical Professor, University of California, Irvine, California.
MEDICAL EXAMINER
Orange County Employees Retirement System, Santa Ana, Orange County, California
MEMBERSHIPS
Orange Country Medical Association
American Society of Clinical Oncology
American College of Physicians
National Hospice Organization
Fellow American College of Physicians
Medical Oncology Association of Southern California
AWARDS
Orange County Medical Association Physician of Excellence Award 2006
Orange County Medical Association Physician of Excellence Award 2007
Corona Chamber of Commerce-Excellent Service Community 2008
Riverside Opportunity Center-Excellent Medicine and Patient Care 2008
BIOGRAPHICAL
Date of Birth: March 14, 1954
Place of Birth: Bombay, India